PLAUR

Across TCGA pan-cancer cohorts, PLAUR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLAUR data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLAUR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLAUR expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LUAD, and GBM are the cancer types where PLAUR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.295	0.511	<.001	95	view →
LUAD	OS	Tertile	All	0.737	0.938	.013	14	view →
GBM	DFS	Median	All	0.278	0.470	.004	9	view →
CCRCC	DFS	Median	III,IV	0.314	0.813	.008	8	view →
HNSC	OS	Median	IV	0.916	0.752	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLAUR–PDAC (DFS)

Open the PDAC breakdown →